Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus

Inclusion Criteria: * Male and female patients age 35 to 65 years of age. * Ability to provide written informed consent. * Mentally stable and able to comply with the procedures of the study protocol. * Clinical history compatible with type 2 diabetes (T2DM) as defined by ADA(1997) on the Diagnosis and classification of Diabetes Mellitus * Basal C-peptide 0.5-2.0 ng/mL * HbA1c ≥ 7.5 and ≤ 11% before standard medical therapy (SMT). * Patients must have been treated with SMT for 1-4 months prior to matching. Insulin dose and metformin doses should be stable over 1 month prior to matching. * HbA1c ≥ 7.5 and ≤ 10% at time of matching. * Total insulin daily dose (TDD) at time of matching should not exceed 1.0 units/day/kg * 18.5 kg/㎡≤BMI≤40.0kg/㎡ Exclusion Criteria: * Abnormal liver function \>2.5 x ULN * Evidence of renal dysfunction:serum creatinine \> 1.5 mg/dl (males) and 1.3 mg/dl (females). * Gastrointestinal operation history. * Type 1 Diabetes mellitus; DKA; secondary diabetes. * Uncontrolled blood Pressure: SBP \>180 mmHg or DBP \>100 mmHg at the time of matching. * Evidence of cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in past 6 months. * Presence of active proliferative diabetic retinopathy or macular edema. * Any acute or chronic infectious condition that in the criteria of the investigator would be a risk for the patient. * For female participants: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. For male participants: intent to procreate 3 months before or after the intervention or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant?, Depo-Provera?, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. * Active infection including hepatitis C, HIV, or TB as determined by a positive skin test or clinical presentation, or under treatment for suspected TB. * Subjects that are being treated with any medication that could interfere with the outcome of the study such as: Thiazolidinediones and other glucagon like peptide 1 (GLP-1) analogues (Exenatide, Byetta), Pramlintide (Amylin), Dipeptidyl-peptidase IV (DPP-IV) inhibitors (i.e. Sitagliptin, Januvia) * Any known or suspected allergy to liraglutide or other relevant products. * Evidence of thyroid adverse events (serum calcitonin increase, goiter, thyroid cancer, et al) or pancreatitis caused by other GLP-1 analogues. * Subjects with past history or family history of Medullary Thyroid Carcinoma(MTC) or Multiple Endocrine Neoplasia Syndrome Type 2(MEN2) .